In a sub-analysis of more than 300 participants from a large clinical trial, individuals regained, on average, two-thirds of the weight they had lost within one year of stopping the medication
Cht ny c s dng rng ri gip chng li cc du hiu lo ha, gip cho ln da khe mnh hn
Clusters 2, 4, and 5 were identified as profibrotic lipid-associated macrophages (LAMs) because of high expression of profibrotic genes (Fn1, Spp1, CD44) and lipid metabolism genes (Lpl, Trem2, Fabp4, Fabp5)
Risks and Considerations The potential benefits of switching medications are compelling, but while this is true, it is also important to carefully weigh tirzepatide vs semaglutide side effects and other risks associated with the switch